LONDON (Alliance News) - Mereo BioPharma Group PLC on Thursday reported positive six-month data for its anti-sclerostin antibody, BPS-804, in the treatment of adult patients with osteogenesis imperfecta.
Mereo BioPharma shares were trading up 14% at 82.99 pence each.
The biopharmaceutical company, focused on rare diseases, said data from the study showed "clear and encouraging percentage changes over baseline in trabecular volumetric bone mineral density".
The company expects 12-month headline data from the blinded arms of the study to be available in the fourth quarter of 2019.
"The data from this open label arm of our phase 2b study is clear and encouraging and in line with our expectations. With 11 patients, we would not expect to see statistical significance and we believe the improvements in bone mineral density observed across patients with all Osteogenesis Imperfecta subtypes included in the trial, bodes well for a positive outcome from the blinded dose arms of the study and we continue to expect headline data from these to be available in the fourth quarter of 2019," Chief Executive Officer Denise Scots-Knight said.